Prospectively documented childhood abuse is associated with a significantly increased long-term risk for adult migraine in men, and depression seems to partially mediate this rela ...

Adults with elevated emotional dysfunction report higher current ADHD symptoms regardless of an actual ADHD diagnosis.

The FDA accepted the NDA for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027.

The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment ...

The use of benzodiazepines among older adults in the US decreased and then plateaued after the COVID-19 pandemic.

The proportion of suspected suicide attempts vs all emergency department visits decreased between 2021 and 2025.

Proposed legislation aims to improve methadone access for opioid use disorder by allowing prescriptions at community pharmacies.

Increased duration of full breastfeeding may reduce the presentation of ADHD symptoms in children aged 3, 5, and 8 years.

Assessing reduced stimulant use in clinical trials may reveal treatment benefits for cocaine and methamphetamine use disorders.

Prefrontal transcranial pulse stimulation offers some antidepressant effects among patients with major depressive disorder.

Twice-daily stable lithium carbonate dosing seems to offer more stable brain lithium levels among euthymic individuals with bipolar disorder.

Fluoxetine, cognitive behavioral therapy, and combined therapy offer similar symptom reduction among youths with anxiety disorders.